Clinical Trials Logo

Human Immunodeficiency Virus clinical trials

View clinical trials related to Human Immunodeficiency Virus.

Filter by:

NCT ID: NCT02515370 Completed - Clinical trials for Human Immunodeficiency Virus

Friends for Life Circles for Option B Plus

FLCs
Start date: May 2016
Phase: N/A
Study type: Interventional

The main goal of the study is to support HIV-infected pregnant women initiated on PMTCT Option B+ during antenatal to adhere to lifelong ART and postpartum care visits through an enhanced group peer support intervention called "friends for life circles".

NCT ID: NCT02514356 Completed - Clinical trials for Human Immunodeficiency Virus

SMS as an Incentive To Adhere (SITA) - An Intervention Communicating Social Norms by SMS to Improve ARV Adherence

SITA
Start date: August 2015
Phase: N/A
Study type: Interventional

The purpose of this study 'SMS as an Incentive To Adhere' (SITA) is to test two novel approaches of using SMS messages (provision of information about electronically measured own adherence, as well as in combination with group adherence level) to improve adherence to anitretroviral (ART) and pre-ART prophylaxis among youth age 15-24 at an HIV clinic in Uganda.

NCT ID: NCT02495779 Completed - Clinical trials for Human Immunodeficiency Virus

Feasibility of Short-Term PrEP Uptake for MSM With Episodic High-Risk for HIV

Start date: July 2015
Phase: N/A
Study type: Interventional

This study is designed to investigate the acceptability, perceived need and uptake of short-term episodic Pre-Exposure Prophylaxis (PrEP) for HIV prevention among men who have sex with men (MSM). The overall objective is to determine the feasibility of a clinic-based Epi-PrEP implementation pilot project for 50 MSM (25/each of the 2 study sites) who report occasional condomless sex and who anticipate a period of high-risk while away from home (e.g. vacation) during the study period.

NCT ID: NCT02491177 Completed - Clinical trials for Human Immunodeficiency Virus

Mother and Infant Visit Adherence and Treatment Engagement Study

MOTIVATE!
Start date: May 2014
Phase: N/A
Study type: Interventional

This is a 2x2 factorial cluster randomized trial of two interventions to improve retention and adherence for women and infants on Option B+. The overall goal is to determine which intervention (or combination of interventions) maximizes antiretroviral therapy (ART) adherence and retention in care in the context of Option B+ and thus improves maternal and infant health outcomes.The proposed study will be conducted in rural Nyanza Province, Kenya at 20 low-resource primary health care facilities and associated communities supported by Family AIDS Care and Education Services (FACES), a President's Emergency Plan for AIDS Relief (PEPFAR)-funded HIV prevention care, and treatment program, ((AIDS) acquired immune deficiency syndrome, (HIV) human immunodeficiency virus) . The investigators will assess both process and outcome indicators using a 2x2 factorial design, in which equal numbers of clusters will be randomized to one of the interventions (community-based mentor mothers or theory-based mobile text messages), both interventions, or standard of care. The interventions will be added to fully integrated high quality HIV and antenatal, maternal, neonatal, and child health (ANC/MNCH) services already offered at these sites.

NCT ID: NCT02481492 Completed - Clinical trials for Human Immunodeficiency Virus

Randomized Controlled Trial of Shang Ring Male Children Circumcision: Comparison Between Flip and No Flip Technique

Start date: June 2015
Phase: N/A
Study type: Interventional

This is a prospect, randomized control trial to evaluate merits between flip and no flip technique in Shang Ring children circumcision.

NCT ID: NCT02479698 Recruiting - Clinical trials for Human Immunodeficiency Virus

Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus

Start date: July 23, 2015
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well donor cytotoxic T lymphocytes work in treating patients with malignancies with BK and/or JC virus. Cytotoxic T lymphocytes are made from donated blood cells that are grown in the laboratory and are designed to kill viruses that can cause infections in transplant patients and may be an effective treatment in patients with malignancies with BK and/or JC virus.

NCT ID: NCT02464423 Completed - Clinical trials for Human Immunodeficiency Virus

Improving Adherence Among HIV+ Rwandan Youth: A TI-CBTe Indigenous Leader Model

Start date: January 2013
Phase: N/A
Study type: Interventional

Like most of sub-Saharan Africa, Rwandan youth are the epicenter of the AIDS epidemic, accounting for 40% of new infections. Antiretroviral (ART) adherence is a global health priority, but Rwandan youth are more than twice as likely to be on second line therapy than adults, and with a median population age of 18.7 years old, adherence is essential for Rwanda's future. Resources to provide youth-centered medical and psychosocial care are limited in Rwanda, and young people with HIV face many obstacles to adherence, namely the long-term consequences of genocide, depression, and gender-based violence, as well as logistical issues, negative attitudes, and insufficient parent/caregiver support. Preliminary data underscore the utility of culturally-adapted, trauma-informed cognitive behavioral therapy (TI-CBT) in reducing depression and traumatic distress among youth and adults in Rwanda. This project proposes a 2-arm randomized controlled trial (RCT) to test and compare the efficacy of adherence-enhanced Trauma Informed Cognitive Behavioral Therapy (i.e., TI-CBTe) to usual care in increasing ART adherence among Rwandan youth from two clinics caring for the largest number of youth with HIV in Rwanda. This proposal answers a compelling need for innovative programs to increase ART adherence among HIV+ youth. If effective, the study will build Rwanda's capacity to provide much needed services; and, involvement by the Rwanda Biomedical Center will ensure wide dissemination.

NCT ID: NCT02462772 Withdrawn - Clinical trials for Human Immunodeficiency Virus

Safety and Acceptability of Cabotegravir in HIV Uninfected Women in KwaZulu-Natal, South Africa

CAPRISA014
Start date: October 2015
Phase: Phase 2
Study type: Interventional

The CAPRISA 014 trial aims to assess the safety and acceptability of the long-acting (LA) injectable antiretroviral agent, cabotegravir LA (GSK1265744), in HIV uninfected women in KwaZulu-Natal, South Africa.

NCT ID: NCT02461576 Completed - Clinical trials for Human Immunodeficiency Virus

Clinical Evaluation of the Xpert® HIV-1 VL

Start date: July 2015
Phase: N/A
Study type: Observational

Compare the clinical performance of the Xpert® HIV-1 VL to another FDA approved HIV-1 RNA quantitative assay using frozen and fresh specimens from known HIV-1 positive individuals.

NCT ID: NCT02459678 Completed - Clinical trials for Human Immunodeficiency Virus

ART Readiness in HIV-infected Pregnant Women

Start date: May 2015
Phase: N/A
Study type: Interventional

This study seeks to evaluate the readiness of HIV-infected pregnant women in Zambia to initiate, adhere to, and be retained in care under the Ministry of Health's Option B+ policy. Under a 3-phased research study the investigators will: (1) conduct formative research regarding readiness to start lifelong ART in the pregnant population; (2) translate the results of formative research into a readiness assessment tool and an enhanced adherence package for pregnant women eligible for Option B+ and (3) conduct an individual randomized trial of the enhanced adherence package.